Antimicrobial and Efflux Pump Inhibitory Activity of Carvotacetones from Sphaeranthus africanus Against Mycobacteria
- PMID: 32650510
- PMCID: PMC7400215
- DOI: 10.3390/antibiotics9070390
Antimicrobial and Efflux Pump Inhibitory Activity of Carvotacetones from Sphaeranthus africanus Against Mycobacteria
Abstract
Carvotacetones (1-7) isolated from Sphaeranthus africanus were screened for their antimycobacterial and efflux pump (EP) inhibitory potential against the mycobacterial model strains Mycobacterium smegmatis mc2 155, Mycobacterium aurum ATCC 23366, and Mycobacterium bovis BCG ATCC 35734. The minimum inhibitory concentrations (MICs) of the carvotacetones were detected through high-throughput spot culture growth inhibition (HT-SPOTi) and microbroth dilution assays. In order to assess the potential of the compounds 1 and 6 to accumulate ethidium bromide (EtBr) in M. smegmatis and M. aurum, a microtiter plate-based fluorometric assay was used to determine efflux activity. Compounds 1 and 6 were analyzed for their modulating effects on the MIC of EtBr and the antibiotic rifampicin (RIF) against M. smegmatis. Carvotacetones 1 and 6 had potent antibacterial effects on M. aurum and M. bovis BCG (MIC ≤ 31.25 mg/L) and could successfully enhance EtBr activity against M. smegmatis. Compound 1 appeared as the most efficient agent for impairing the efflux mechanism in M. smegmatis. Both compounds 1 and 6 were highly effective against M. aurum and M. bovis BCG. In particular, compound 1 was identified as a valuable candidate for inhibiting mycobacterial efflux mechanisms and as a promising adjuvant in the therapy of tuberculosis or other non-tubercular mycobacterial infections.
Keywords: Compositae; Sphaeranthus africanus L.; carvotacetones; efflux pump inhibitors; efflux pumps; ethidium bromide accumulation; mycobacteria.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7400215/bin/antibiotics-09-00390-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7400215/bin/antibiotics-09-00390-g002.gif)
Similar articles
-
Flavonoids as Novel Efflux Pump Inhibitors and Antimicrobials Against Both Environmental and Pathogenic Intracellular Mycobacterial Species.Molecules. 2020 Feb 7;25(3):734. doi: 10.3390/molecules25030734. Molecules. 2020. PMID: 32046221 Free PMC article.
-
Putative mycobacterial efflux inhibitors from the seeds of Aframomum melegueta.J Nat Prod. 2012 Jul 27;75(7):1393-9. doi: 10.1021/np300375t. Epub 2012 Jul 13. J Nat Prod. 2012. PMID: 22789014
-
Farnesol, a potential efflux pump inhibitor in Mycobacterium smegmatis.Molecules. 2010 Oct 29;15(11):7750-62. doi: 10.3390/molecules15117750. Molecules. 2010. PMID: 21042264 Free PMC article.
-
Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis.J Antimicrob Chemother. 2008 Aug;62(2):345-8. doi: 10.1093/jac/dkn178. Epub 2008 Apr 21. J Antimicrob Chemother. 2008. PMID: 18430720
-
The evaluation of forty-three plant species for in vitro antimycobacterial activities; isolation of active constituents from Psoralea corylifolia and Sanguinaria canadensis.J Ethnopharmacol. 2002 Jan;79(1):57-67. doi: 10.1016/s0378-8741(01)00350-6. J Ethnopharmacol. 2002. PMID: 11744296 Review.
Cited by
-
Understanding the Phage-Host Interaction Mechanism toward Improving the Efficacy of Current Antibiotics in Mycobacterium abscessus.Biomedicines. 2023 May 6;11(5):1379. doi: 10.3390/biomedicines11051379. Biomedicines. 2023. PMID: 37239050 Free PMC article.
-
Essential Oils from Vietnamese Asteraceae for Environmentally Friendly Control of Aedes Mosquitoes.Molecules. 2022 Nov 17;27(22):7961. doi: 10.3390/molecules27227961. Molecules. 2022. PMID: 36432060 Free PMC article.
-
Bioactive Compounds from the Bornean Endemic Plant Goniothalamus longistipetes.Antibiotics (Basel). 2020 Dec 16;9(12):913. doi: 10.3390/antibiotics9120913. Antibiotics (Basel). 2020. PMID: 33339285 Free PMC article.
References
-
- Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D.L., Pulcini C., Kahlmeter G., Kluytmans J., Carmeli Y. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018;18:318–327. doi: 10.1016/S1473-3099(17)30753-3. - DOI - PubMed
LinkOut - more resources
Full Text Sources